Literature DB >> 12322720

The Orphan Drug Act: an engine of innovation? At what cost?

D D Rohde1.   

Abstract

Mesh:

Year:  2000        PMID: 12322720

Source DB:  PubMed          Journal:  Food Drug Law J        ISSN: 1064-590X            Impact factor:   0.619


× No keyword cloud information.
  6 in total

1.  Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development".

Authors:  Aidan Hollis
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Access to orphan drugs in the Middle East: Challenge and perspective.

Authors:  Ziyad S Almalki; Abdullah K Alahmari; Jeff J Guo; Christina M L Kelton
Journal:  Intractable Rare Dis Res       Date:  2012-11

3.  Use of Graph Database for the Integration of Heterogeneous Biological Data.

Authors:  Byoung-Ha Yoon; Seon-Kyu Kim; Seon-Young Kim
Journal:  Genomics Inform       Date:  2017-03-29

4.  Pivotal studies of orphan drugs approved for neurological diseases.

Authors:  Jun Mitsumoto; E Ray Dorsey; Christopher A Beck; Karl Kieburtz; Robert C Griggs
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

5.  The prevalence and cost of unapproved uses of top-selling orphan drugs.

Authors:  Aaron S Kesselheim; Jessica A Myers; Daniel H Solomon; Wolfgang C Winkelmayer; Raisa Levin; Jerry Avorn
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

6.  Incentives for orphan drug research and development in the United States.

Authors:  Enrique Seoane-Vazquez; Rosa Rodriguez-Monguio; Sheryl L Szeinbach; Jay Visaria
Journal:  Orphanet J Rare Dis       Date:  2008-12-16       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.